Maravai LifeSciences
MRVI
221 hedge funds and large institutions have $1.58B invested in Maravai LifeSciences in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 72 increasing their positions, 82 reducing their positions, and 41 closing their positions.
7% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 41
1% more funds holding
Funds holding: 219 → 221 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.05% less ownership
Funds ownership: 97.24% → 96.18% (-1.1%)
12% less capital invested
Capital invested by funds: $1.79B → $1.58B (-$213M)
12% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 82
78% less call options, than puts
Call options by funds: $2.72M | Put options by funds: $12.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$24.4M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.8M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$22.6M |
| 4 |
RI
RTW Investments
New York
|
+$20.7M |
| 5 |
N
Natixis
Paris,
France
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCBV
Ownership Capital B.V.
Amsterdam,
Netherlands
|
-$53.2M |
| 2 |
JP Morgan Chase
New York
|
-$48.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$30.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$22.9M |
| 5 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$17.3M |
MRVI Hedge Fund Activity: Q2 2023 in Review
221 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2023, worth a combined $1.58B — down 12% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new MRVI positions and 41 closed out — a net gain of 3 holders — while 72 added to existing stakes and 82 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $24.4M. The largest seller was Ownership Capital B.V., exiting entirely with an estimated $53.2M sold.
- 221 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2023, up from 219 in Q1 2023.
- Funds reported $1.58B of Maravai LifeSciences stock for Q2 2023, down 12% quarter-over-quarter.
- 44 funds opened new Maravai LifeSciences positions in Q2 2023 and 41 closed out, a net change of +3 holders.
- The largest Maravai LifeSciences buyer in Q2 2023 was Braidwell, an estimated $24.4M added.
- The largest Maravai LifeSciences seller in Q2 2023 was Ownership Capital B.V., an estimated $53.2M sold.
Based on aggregated 13F filings for Q2 2023.